Overexpression of Lewis y antigen promotes human epididymis protein 4-mediated invasion and metastasis of ovarian cancer cells

Biochimie

Volumn 105, Issue , 2014, Pages 91-98

  Zhuang, Huiyu ^a   Hu, Zhenhua ^a   Tan, Mingzi ^a   Zhu, Liancheng ^a   Liu, Juanjuan ^a   Liu, Dawo ^a   Yan, Limei ^a   Lin, Bei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Human epididymis protein 4; Invasion; Lewis y antigen; Metastasis; Ovarian cancer

Indexed keywords

BLOCKING ANTIBODY; HUMAN EPIDIDYMIS PROTEIN 4; BLOOD GROUP LEWIS SYSTEM; LEWIS Y ANTIGEN; PROTEIN; WFDC2 PROTEIN, HUMAN;

ARTICLE; BLOOD GROUP LEWIS SYSTEM; CANCER CELL; FUCOSYLATION; HUMAN; HUMAN CELL; METASTASIS; OVARY CANCER; TUMOR INVASION; BIOSYNTHESIS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEWIS BLOOD-GROUP SYSTEM; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROTEINS;

EID: 84907809637     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2014.06.022     Document Type: Article

References (24)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 2013 11 30
2. N. Husseinzadeh Status of tumor markers in epithelial ovarian cancer has there been any progress? a review Gynecol. Oncol. 120 2011 152 157
3. I. Hellstrom, J. Raycraft, M. Hayden-Ledbetter, J.A. Ledbetter, M. Schummer, M. McIntosh, C. Drescher, N. Urban, and K.E. Hellstrom The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res. 63 2003 3695 3700
4. R.G. Moore, D.S. McMeekin, A.K. Brown, P. DiSilvestro, M.C. Miller, W.J. Allard, W. Gajewski, R. Kurman, R.C. Bast Jr., and S.J. Skates A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol. Oncol. 112 2009 40 46
5. E. Bignotti, M. Ragnoli, L. Zanotti, S. Calza, M. Falchetti, S. Lonardi, S. Bergamelli, E. Bandiera, R.A. Tassi, C. Romani, P. Todeschini, F.E. Odicino, F. Facchetti, S. Pecorelli, and A. Ravaggi Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients Br. J. Cancer 104 2011 1418 1425
6. K. Tokuishi, S. Yamashita, K. Ohbo, and K. Kawahara Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma Tumour Biol. 33 2012 103 109
7. R. Drapkin, H.H. von Horsten, Y. Lin, S.C. Mok, C.P. Crum, W.R. Welch, and J.L. Hecht Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas Cancer Res. 65 2005 2162 2169
8. H. Kimura, N. Shinya, S. Nishihara, M. Kaneko, T. Irimura, and H. Narimatsu Distinct substrate specificities of five human alpha-1,3-fucosyltransferases for in vivo synthesis of the sialyl Lewis x and Lewis x epitopes Biochem. Biophys. Res. Commun. 237 1997 131 137
9. H. Zhuang, J. Gao, Z. Hu, J. Liu, D. Liu, and B. Lin Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma PLoS One 8 2013 e68994
10. W.M. Lin, U. Karsten, S. Goletz, R.C. Cheng, and Y. Cao Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells Virchows Arch. 456 2010 403 409
11. R. Lu, X. Sun, R. Xiao, L. Zhou, X. Gao, and L. Guo Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility Biochem. Biophys. Res. Commun. 419 2012 274 280
12. Y.F. Zhu, G.L. Gao, S.B. Tang, Z.D. Zhang, and Q.S. Huang Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro Asian Pac. J. Trop. Med. 6 2013 265 272
13. K. Moriwaki, and E. Miyoshi Fucosylation and gastrointestinal cancer World J. hepatol. 2 2010 151 161
14. D.C. Chhieng, C. Rodriguez-Burford, L.I. Talley, H. Sviglin, C.R. Stockard, M.J. Kleinberg, M.N. Barnes, E.E. Partridge, M.B. Khazaeli, and W.E. Grizzle Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma Hum. Pathol. 34 2003 1016 1021
15. Q. Li, S. Liu, B. Lin, L. Yan, Y. Wang, C. Wang, and S. Zhang Expression and correlation of Lewis y antigen and integrins alpha5 and beta1 in ovarian serous and mucinous carcinoma Int. J. Gynecol. Cancer 20 2010 1482 1489
16. B.W. Yin, C.L. Finstad, K. Kitamura, M.G. Federici, M. Welshinger, V. Kudryashov, W.J. Hoskins, S. Welt, and K.O. Lloyd Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer Int. J. Cancer 65 1996 406 412
17. J.J. Liu, B. Lin, Y.Y. Hao, F.F. Li, D.W. Liu, Y. Qi, L.C. Zhu, S.L. Zhang, and M. Iwamori Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway Oncol. Rep. 23 2010 833 841
18. L.M. Yan, B. Lin, L.C. Zhu, Y.Y. Hao, Y. Qi, C.Z. Wang, S. Gao, S.C. Liu, S.L. Zhang, and M. Iwamori Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene Biochimie 92 2010 852 857
19. L. Gao, L. Yan, B. Lin, J. Gao, X. Liang, Y. Wang, J. Liu, S. Zhang, and M. Iwamori Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I J. Exp. Clin. Cancer Res. 30 2011 15
20. X. Wang, J. Gu, H. Ihara, E. Miyoshi, K. Honke, and N. Taniguchi Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling J. Biol. Chem. 281 2006 2572 2577
21. M. Iwamori, K. Tanaka, K. Kubushiro, B. Lin, K. Kiguchi, I. Ishiwata, K. Tsukazaki, and S. Nozawa Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the alpha1,2-fucosyltransferase gene Cancer Sci. 96 2005 26 30
22. P.J. Sabbatini, V. Kudryashov, G. Ragupathi, S.J. Danishefsky, P.O. Livingston, W. Bornmann, M. Spassova, A. Zatorski, D. Spriggs, C. Aghajanian, S. Soignet, M. Peyton, C. O'Flaherty, J. Curtin, and K.O. Lloyd Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial Int. J. Cancer 87 2000 79 85
23. S.F. Slovin, G. Ragupathi, C. Fernandez, M. Diani, M.P. Jefferson, A. Wilton, W.K. Kelly, M. Morris, D. Solit, H. Clausen, P. Livingston, and H.I. Scher A polyvalent vaccine for high-risk prostate patients: "are more antigens better?" Cancer Immunol. Immunother. 56 2007 1921 1930
24. P.J. Sabbatini, G. Ragupathi, C.A. Aghajanian, C. Hood, M. Juretzka, A. Iasonos, M.L. Hensley, M.K. Spassova, O. Ouerfelli, D.R. Spriggs, W.P. Tew, J. Konner, H. Clausen, R.N. Abu, S.J. Dansihefsky, and P.O. Livingston Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer Clin. Cancer Res. 14 2007 2631 2638